NEW HAVEN, Conn.—Yarrow Bioscience, Inc. (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing therapies for autoimmune thyroid diseases, announced the pricing of its previously announced underwritten public offering of 5,769,231 shares of its common stock at a public offering price per share of $26.00. The aggregate gross proceeds to Yarrow from the offering are expected to be approximately $150 million. The offering is expected to close on September 14, 2026, subject to the satisfaction of customary closing conditions, the announcement noted.